Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback